Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2025-12-24 @ 11:52 PM
NCT ID:
NCT05343351
Eligibility Criteria:
Inclusion Criteria:
* Age ≥18
* Numbness and tingling in the median nerve innervation area with or without pain
* Worsening of symptoms at night
* Positive Tinel and/or Phalen sign
* Symptom duration longer than 12 weeks
* Electrophysiologically mild or moderate CTS being diagnosed.
Exclusion Criteria:
* Presence of conditions such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome that may mimic CTS
* Presence of multiple entrapment neuropathy
* Weakness in hand thumb abduction or opposition
* Thenar atrophy
* Presence of wrist corticosteroid and/or local anesthetic injection
* Regular use of medical treatment such as oral corticosteroids or NSAIDs
* Having entered a physical therapy program due to CTS in the last 6 months before the injection
* A history of trauma or arthritis attack at the wrist level
* Previous surgery due to CTS
* Thyroid diseases, diabetes, chronic kidney failure
* Having bifid median nerve, persistent median artery, ganglion cyst, tenosynovitis or tendinitis on wrist USG
* Rheumatological disease (rheumatoid arthritis, ankylosing spondylitis, systemic lupus) erythematosus, vasculitis, systemic sclerosis, dermatomyositis)
* Presence of malignancy
* Pregnant or breastfeeding mothers
* Infection or skin lesion at the injection site
* Use of wrist splints in the last 4 weeks
* Allergy to corticosteroids or local anesthetics
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05343351
Study Brief:
Protocol Section:
NCT05343351